David A. Siegel Avadel Pharmaceuticals PLC Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$8.48 - $16.48 $159,424 - $309,824
18,800 Added 17.79%
124,500 $2.05 Million
Q1 2023

May 15, 2023
BUY
$6.41 - $9.95 $80,766 - $125,369
12,600 Added 13.53%
105,700 $968,000
Q4 2022

Feb 14, 2023
SELL
$5.02 - $10.0 $13,553 - $27,000
-2,700 Reduced 2.82%
93,100 $666,000
Q3 2022

Nov 14, 2022
BUY
$2.57 - $7.31 $170,391 - $484,653
66,300 Added 224.75%
95,800 $480,000
Q2 2022

Aug 15, 2022
BUY
$1.07 - $6.95 $31,565 - $205,025
29,500 New
29,500 $72,000

Others Institutions Holding AVDL

# of Institutions
8
Shares Held
1.07M
Call Options Held
0
Put Options Held
0
View Full List

About AVADEL PHARMACEUTICALS PLC

AVDL Quotes by TradingView
  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $625M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email